Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
6.27
+2.08 (49.64%)
At close: Oct 23, 2026, 4:00 PM EDT
6.86
+0.59 (9.41%)
After-hours: Oct 23, 2026, 7:59 PM EDT
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $5.00K in the quarter ending June 30, 2026, a decrease of -99.72%. This brings the company's total for the last twelve months to $4.70M, up 12.79% year-over-year. In the year 2025, Bolt Biotherapeutics had annual revenue of $7.70M with 0.07% growth. That makes Bolt Biotherapeutics the 40,131st largest company in the world by revenue and 5,335th in the United States.
Revenue (ttm)
$4.70M
Revenue Growth
+12.79%
P/S Ratio
2.57
Revenue / Employee
$204,348
Employees
23
Market Cap
12.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 5.00K | 0.07% |
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | 215.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Cerenome | 4.20M |
| SeaStar Medical Holding | 1.71M |
| Lipocine | 1.57M |
| Daré Bioscience | 1.37M |
| Pluri | 1.02M |
| Vyome Holdings | 129.73K |
BOLT News
- Just now - Bolt Biotherapeutics Press release: M&A announcement - Filings
- 1 day ago - Why Is Penny Stock Bolt Biotherapeutics (BOLT) Up 62% Today? - TipRanks
- 1 day ago - Bolt Biotherapeutics Inc trading resumes - TheFly
- 1 day ago - Bolt Biotherapeutics acquires Prana Therapies - TheFly
- 1 day ago - Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications - GlobeNewsWire
- 1 day ago - Bolt Biotherapeutics Inc trading halted, news pending - TheFly
- 2 months ago - Bolt Biotherapeutics reports Q2 EPS ($4.57) vs. ($4.46) last year - TheFly
- 2 months ago - Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire